[go: up one dir, main page]

MX2018008645A - Derivados de 8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano. - Google Patents

Derivados de 8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano.

Info

Publication number
MX2018008645A
MX2018008645A MX2018008645A MX2018008645A MX2018008645A MX 2018008645 A MX2018008645 A MX 2018008645A MX 2018008645 A MX2018008645 A MX 2018008645A MX 2018008645 A MX2018008645 A MX 2018008645A MX 2018008645 A MX2018008645 A MX 2018008645A
Authority
MX
Mexico
Prior art keywords
diaza
oxo
derivatives
amino
espiro
Prior art date
Application number
MX2018008645A
Other languages
English (en)
Other versions
MX379359B (es
Inventor
Linz Klaus
Kühnert Sven
Jostock Ruth
Kless Achim
Ratcliffe Paul
Michael Koenigs René
WEGERT Anita
Koch Thomas
Schröder Wolfgang
Original Assignee
Gruenenthal Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gruenenthal Gmbh filed Critical Gruenenthal Gmbh
Publication of MX2018008645A publication Critical patent/MX2018008645A/es
Publication of MX379359B publication Critical patent/MX379359B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La invención se refiere a derivados de 8-amino-2-oxo-1,3-diaza-esp iro-[4.5]-decano, su preparación y su uso en medicamentos, en particular en el tratamiento del dolor.
MX2018008645A 2016-01-13 2017-01-13 Derivados de 8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano. MX379359B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16151015 2016-01-13
PCT/EP2017/025008 WO2017121650A1 (en) 2016-01-13 2017-01-13 8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives

Publications (2)

Publication Number Publication Date
MX2018008645A true MX2018008645A (es) 2018-11-19
MX379359B MX379359B (es) 2025-03-11

Family

ID=55129636

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018008645A MX379359B (es) 2016-01-13 2017-01-13 Derivados de 8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano.

Country Status (26)

Country Link
US (7) US20170197949A1 (es)
EP (1) EP3402782B1 (es)
JP (1) JP6917379B2 (es)
KR (1) KR20180097734A (es)
CN (1) CN108602778B (es)
AR (1) AR107359A1 (es)
AU (1) AU2017206911B2 (es)
BR (1) BR112018014301B1 (es)
CA (1) CA3011182A1 (es)
CL (1) CL2018001909A1 (es)
CO (1) CO2018008450A2 (es)
CY (1) CY1123366T1 (es)
DK (1) DK3402782T3 (es)
EA (1) EA034898B1 (es)
EC (1) ECSP18060875A (es)
ES (1) ES2821969T3 (es)
HR (1) HRP20201660T1 (es)
HU (1) HUE051642T2 (es)
IL (1) IL260488B (es)
LT (1) LT3402782T (es)
MX (1) MX379359B (es)
PT (1) PT3402782T (es)
RS (1) RS60855B1 (es)
SI (1) SI3402782T1 (es)
TW (1) TWI654181B (es)
WO (1) WO2017121650A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6862457B2 (ja) 2016-01-13 2021-04-21 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング ３−（カルボキシメチル）−８−アミノ−２−オキソ−１，３−ジアザ−スピロ−［４．５］−デカン誘導体
ES2807549T3 (es) 2016-01-13 2021-02-23 Gruenenthal Gmbh Derivados de 3-((hetero)-aril)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano
PE20181375A1 (es) 2016-01-13 2018-08-28 Gruenenthal Chemie Derivados de 3-((hetero)aril)-alquil-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano
HRP20200809T1 (hr) 2016-01-13 2020-08-07 Grünenthal GmbH Derivati 3-(karboksimetil)-8-amino-2-okso-1,3-diaza-spiro-[4.5]-dekana
MX379359B (es) 2016-01-13 2025-03-11 Gruenenthal Gmbh Derivados de 8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano.
WO2019039852A1 (ko) 2017-08-22 2019-02-28 주식회사 엘지화학 방열 소재 디스펜싱 장치의 결정방법
PE20211733A1 (es) 2019-01-11 2021-09-06 Gruenenthal Chemie Amidas de pirrolidina sustituidas
CN110092790B (zh) * 2019-06-11 2020-07-24 东北农业大学 一种生物碱类化合物及其制备方法和应用
US20240400537A1 (en) 2023-04-25 2024-12-05 Gruenenthal Gmbh Cis-8-(3,5-difluorophenyl)-8-(dimethylamino)-1,3-diazaspiro[4.5]decan-2-one derivatives

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2734265B1 (fr) 1995-05-17 1997-06-13 Adir Nouveaux composes spiro heterocycliques, leur procede de preparation et les compositions pharmaceutiques les contenant
KR100729242B1 (ko) 2001-04-18 2007-06-15 유로-셀티크 소시에떼 아노뉨 노시셉틴 유사체
DE10130020A1 (de) 2001-06-25 2003-12-04 Gruenenthal Gmbh Substituierte 1-Oxa-2,8-diaza-spiro[4.5]dec-2-en-derivate
DE10135636A1 (de) * 2001-07-17 2003-02-06 Gruenenthal Gmbh Substituierte 4-Aminocyclohexanole
DE10210195B4 (de) 2002-03-07 2005-12-15 Schwarz Pharma Ag Verwendung von 1,3-Diazaspiro-[4,5]decan-2,4-dithion zur Behandlung von Schmerz
EP1519939B9 (en) 2002-07-05 2011-04-06 Targacept, Inc. N-aryl diazaspirocyclic compounds and methods of preparation and use thereof
DE10252667A1 (de) 2002-11-11 2004-05-27 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
ZA200510329B (en) 2003-05-23 2007-04-25 Zealand Pharma As Triaza-spiro compounds as nociceptin analogues and uses thereof
JO2676B1 (en) 2004-04-06 2012-06-17 جانسين فارماسوتيكا ان. في Derivatives of second-aza-spiro- (5,4) -dikan and their use as antihistamines
DE102005044813A1 (de) 2005-05-19 2007-10-04 Grünenthal GmbH Substituierte Spiro-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln
DE102005023784A1 (de) 2005-05-19 2006-11-30 Grünenthal GmbH Substituierte Spiro-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln
DE102005030051A1 (de) 2005-06-27 2006-12-28 Grünenthal GmbH Substituierte 1-Oxa-3,8-diazaspiro[4,5]-decan-2-on-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln
DE102006019597A1 (de) 2006-04-27 2007-10-31 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
BRPI0717657A2 (pt) 2006-10-19 2013-12-24 Hoffmann La Roche Compostos, processo para a preparação de um composto, composição farmacêutica que o compreende, usos de compostos, métodos para o tratamento e profilaxia de diabetes, obesidade, distúrbios alimentares, displidemia e hipertensão e profilaxia de diabetes do tipo ii
CN101679430B (zh) 2007-04-09 2013-12-25 詹森药业有限公司 用于治疗焦虑和抑郁症的作为orl-1受体的配体的1,3,8-三取代-1,3,8-三氮杂-螺[4.5]癸-4-酮衍生物
NZ588779A (en) 2008-03-27 2012-06-29 Gruenenthal Chemie Substituted 4-aminocyclohexane derivatives
TW201038572A (en) 2009-03-25 2010-11-01 Gruenenthal Gmbh Substituted spiro-amide compounds
WO2010151815A2 (en) 2009-06-25 2010-12-29 Abbott Laboratories 3,9-diazaspiro[5,5]undecane amides and ureas and methods of use thereof
TWI582092B (zh) 2010-07-28 2017-05-11 歌林達股份有限公司 順式－四氫－螺旋（環己烷－１,１’－吡啶［３,４－b］吲哚）－４－胺－衍生物
WO2014106238A1 (en) * 2012-12-31 2014-07-03 Fang, Qun, Kevin Heterocyclic compounds and methods of use thereof
KR102425400B1 (ko) * 2014-03-14 2022-07-26 라퀄리아 파마 인코포레이티드 Trpm8 길항제로 사용되는 아자스피로 유도체
EP3154971A4 (en) 2014-06-13 2017-11-01 Purdue Pharma L.P. Heterocyclic morphinan derivatives and use thereof
PE20181375A1 (es) 2016-01-13 2018-08-28 Gruenenthal Chemie Derivados de 3-((hetero)aril)-alquil-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano
MX379359B (es) 2016-01-13 2025-03-11 Gruenenthal Gmbh Derivados de 8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano.
AR107354A1 (es) 2016-01-13 2018-04-18 Bristol Myers Squibb Co Salicilamidas espiroheptanos y compuestos relacionados como inhibidores de rock
JP6862457B2 (ja) 2016-01-13 2021-04-21 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング ３−（カルボキシメチル）−８−アミノ−２−オキソ−１，３−ジアザ−スピロ−［４．５］−デカン誘導体
LT3402811T (lt) 2016-01-13 2022-06-10 Novo Nordisk A/S Egf(a) analogai su riebalų rūgščių pakaitais
ES2807549T3 (es) 2016-01-13 2021-02-23 Gruenenthal Gmbh Derivados de 3-((hetero)-aril)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano
HRP20200809T1 (hr) 2016-01-13 2020-08-07 Grünenthal GmbH Derivati 3-(karboksimetil)-8-amino-2-okso-1,3-diaza-spiro-[4.5]-dekana

Also Published As

Publication number Publication date
BR112018014301B1 (pt) 2023-10-31
KR20180097734A (ko) 2018-08-31
LT3402782T (lt) 2020-10-12
CA3011182A1 (en) 2017-07-20
RS60855B1 (sr) 2020-10-30
US20210179595A1 (en) 2021-06-17
AR107359A1 (es) 2018-04-25
MX379359B (es) 2025-03-11
HRP20201660T1 (hr) 2021-03-05
EA034898B1 (ru) 2020-04-03
CY1123366T1 (el) 2021-12-31
US20170197949A1 (en) 2017-07-13
EP3402782A1 (en) 2018-11-21
CL2018001909A1 (es) 2018-10-19
US10793556B2 (en) 2020-10-06
EP3402782B1 (en) 2020-07-29
ECSP18060875A (es) 2018-08-31
SI3402782T1 (sl) 2020-11-30
US20200399255A1 (en) 2020-12-24
CN108602778B (zh) 2021-12-10
AU2017206911A1 (en) 2018-08-30
JP2019501932A (ja) 2019-01-24
IL260488B (en) 2021-09-30
EA201891608A1 (ru) 2019-01-31
PT3402782T (pt) 2020-10-01
JP6917379B2 (ja) 2021-08-11
AU2017206911B2 (en) 2020-07-09
US20190100515A1 (en) 2019-04-04
TWI654181B (zh) 2019-03-21
TW201730155A (zh) 2017-09-01
CN108602778A (zh) 2018-09-28
WO2017121650A1 (en) 2017-07-20
DK3402782T3 (da) 2020-09-28
ES2821969T3 (es) 2021-04-28
US20230183222A1 (en) 2023-06-15
US20190375738A1 (en) 2019-12-12
NZ745186A (en) 2024-05-31
US20180273516A1 (en) 2018-09-27
HUE051642T2 (hu) 2021-03-01
CO2018008450A2 (es) 2018-09-20
BR112018014301A2 (pt) 2018-12-11

Similar Documents

Publication Publication Date Title
ECSP18060875A (es) Derivados de 8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano
ECSP18060848A (es) Derivados de 3-((hetero)aril)-alquil-8-amino-2-oxo-1,3-diaza-espiro-[ 4.5]-decano
CL2018001624A1 (es) Antagonistas policíclicos del tlr7/8 y uso de los mismos en el tratamiento de trastornos inmunitarios
MX390014B (es) Compuestos de dinucleótidos cíclicos y métodos de uso.
ECSP18060820A (es) Derivados de 3-(carboxietil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]- decano
CO2017001994A2 (es) Compuestos activos hacia bromodominios
ECSP18060864A (es) Derivados de 3-(carboximetil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]- decano
ECSP18060834A (es) Derivados de 3-((hetero)aril)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]- decano
MX2018012285A (es) Metodos de tratamiento para enfermedades colestasicas y fibroticas.
MX389026B (es) Una composicion farmaceutica y el uso de la misma.
CL2019002480A1 (es) Derivados de pirazol como inhibidores de bromodominio.
ECSP16086247A (es) (s)-pirlindole y sus sales farmacéuticamente aceptables para uso en medicina
CL2018002368A1 (es) Formulaciones de oritavancina
MX2016014701A (es) (r)-pirlindol y sus sales farmaceuticamente aceptables para uso en medicina.
MX2018012223A (es) Formulaciones liquidas de fosfaplatino.
MX2019009909A (es) Composiciones farmaceuticas para terapia de combinacion.